About the Authors
- Xingsheng Hu
-
Contributed equally to this work with: Xingsheng Hu, Li Zhang
Affiliation Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
- Li Zhang
-
Contributed equally to this work with: Xingsheng Hu, Li Zhang
Affiliation Sun Yat-Sen University Cancer Center, Guangzhou, China
- Yuankai Shi
-
Affiliation Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
- Caicun Zhou
-
Affiliation Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
- Xiaoqing Liu
-
Affiliation Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing, China
- Dong Wang
-
Affiliation Third Affiliated Hospital, The Third Military Medical University of People‘s Liberation Army, Chongqing, China
- Yong Song
-
Affiliation Nanjing Military General Hospital, Nanjing, China
- Qiang Li
-
Affiliation Changhai Hospital, The Second Military Medical University, Shanghai, China
- Jifeng Feng
-
Affiliation Jiangsu Province Cancer Hospital, Nanjing, China
- Shukui Qin
-
Affiliation Nanjing Bayi Hospital of People’s Liberation Army, Nanjing, China
- Nong Xv
-
Affiliation The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China
- Jianying Zhou
-
Affiliation The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China
- Li Zhang
-
Affiliation Peking Union Medical College Hospital, Beijing, China
- Chunhong Hu
-
Affiliation The Second Xiangya Hospital, Changsha, China
- Shucai Zhang
-
Affiliation Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
- Rongcheng Luo
-
Affiliation Nanfang Hospital, Southern Medical University, Guangzhou, China
- Jie Wang
-
Affiliation Beijing Cancer Hospital, Beijing, China
- Fenlai Tan
-
Affiliation Betta Pharmaceuticals Co, Ltd, Hangzhou, China
- Yinxiang Wang
-
Affiliation Betta Pharmaceuticals Co, Ltd, Hangzhou, China
- Lieming Ding
-
Affiliation Betta Pharmaceuticals Co, Ltd, Hangzhou, China
- Yan Sun
-
* E-mail: suny@csco.org.cn
Affiliation Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Competing Interests
The authors of this manuscript have the following competing interests: Fenlai Tan, Yinxiang Wang, and Lieming Ding are salaried employees of Betta Pharmaceuticals Co, Ltd. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. All other authors had no competing interests.
Author Contributions
Conceived and designed the experiments: XSH LZ (2nd author) YKS CCZ XQL DW YongS QL JFF SKQ NX JYZ LZ (13th author) CHH SCZ RCL JW FLT YXW LMD YanS. Performed the experiments: XSH LZ (2nd author) YKS CCZ XQL DW YongS QL JFF SKQ NX JYZ LZ (13th author)CHH SCZ RCL JW YanS. Analyzed the data: XSH LZ (2nd author)YKS FLT YXW LMD YanS. Contributed reagents/materials/analysis tools: XSH LZ (2nd author) YKS FLT YXW LMD YanS. Wrote the paper: XSH LZ (2nd author) YKS CCZ XQL DW YongS QL JFF SKQ NX JYZ LZ (13th author) CHH SCZ RCL JW FLT YXW LMD YanS.